RxDoctor Payments Data

Luca Paoletti, MD

Critical Care Medicine · Charleston, SCNPI 1639378367

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim at 41.0% of the total. Reporting peaked in 2022 at $3,243 and has fallen 85.4% since, to $472 in 2025.

$5,463in general payments, 2019–2025

Across 21 payments — averaging $260.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Abbott$447
  • La Jolla Pharmaceutical Company$297
  • United Therapeutics Corporation$255
  • Medtronic$156
  • plus $329 from 5 others

What the payments were for

  • Consulting fees$1,74032%
  • Speaking & faculty fees$2,23941%
  • Food & beverage$1,48427%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,463 in reported general payments places this provider in the 80th percentile of 93 critical care medicine providers in South Carolina.

See all critical care medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$73,828
Medicare patients
555
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate165$1,884,885
Pirfenidone53$132,109
Atovaquone51$32,240
Posaconazole18$26,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,182
Tacrolimus65$11,609
Mycophenolate Mofetil43$5,137
Valganciclovir Hcl18$4,263
Azithromycin51$1,371
Pantoprazole Sodium50$1,242
Acyclovir50$1,167
Famotidine71$1,040
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$963
Prednisone75$767
Atorvastatin Calcium20$663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$2,239$1,884,885165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 critical care medicine providers in South Carolina.

Other critical care medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →